Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBVNYSE:JNJNYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$205.12+1.2%$197.50$153.58▼$218.66$362.85B0.615.70 million shs6.48 million shsJNJJohnson & Johnson$163.63+0.3%$158.68$140.68▼$169.99$394.32B0.477.63 million shs5.76 million shsMRKMerck & Co., Inc.$89.18+1.8%$91.92$81.04▼$134.63$221.28B0.3511.05 million shs12.39 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.81%-4.13%-0.68%+13.92%+12.44%JNJJohnson & Johnson+0.97%+0.18%-1.75%+12.52%+3.33%MRKMerck & Co., Inc.-0.52%-7.52%-4.26%-12.14%-33.51%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.5232 of 5 stars2.53.03.33.93.52.51.3JNJJohnson & Johnson4.4036 of 5 stars2.33.04.23.93.52.50.6MRKMerck & Co., Inc.5 of 5 stars4.35.05.03.92.73.33.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.92Moderate Buy$211.453.09% UpsideJNJJohnson & Johnson 2.56Moderate Buy$171.334.71% UpsideMRKMerck & Co., Inc. 2.65Moderate Buy$117.1231.33% UpsideCurrent Analyst Ratings BreakdownLatest MRK, JNJ, and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/17/2025ABBVAbbVieErste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/10/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/5/2025ABBVAbbVieWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$210.00 ➝ $240.003/5/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$159.00 ➝ $171.003/4/2025ABBVAbbVieBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$200.00 ➝ $223.002/19/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.002/18/2025MRKMerck & Co., Inc.Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$128.00 ➝ $105.002/12/2025MRKMerck & Co., Inc.GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $115.002/10/2025MRKMerck & Co., Inc.TD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$121.00 ➝ $100.002/10/2025MRKMerck & Co., Inc.TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$121.00 ➝ $100.002/5/2025MRKMerck & Co., Inc.Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$118.00 ➝ $112.00(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.44$15.16 per share13.53$1.90 per share107.96JNJJohnson & Johnson$88.82B4.44$13.45 per share12.17$29.69 per share5.51MRKMerck & Co., Inc.$64.17B3.51$3.09 per share28.82$14.85 per share6.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.4085.4714.671.627.59%296.28%12.65%4/25/2025 (Estimated)JNJJohnson & Johnson$14.07B$6.6524.6114.782.5618.20%34.24%13.63%4/15/2025 (Estimated)MRKMerck & Co., Inc.$17.12B$6.7313.259.010.7726.67%45.35%17.36%4/24/2025 (Estimated)Latest MRK, JNJ, and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/25/2025N/AABBVAbbVie$2.51N/AN/AN/A$12.91 billionN/A4/24/2025N/AMRKMerck & Co., Inc.$2.16N/AN/AN/A$15.59 billionN/A4/15/2025N/AJNJJohnson & Johnson$2.59N/AN/AN/A$21.65 billionN/A2/4/2025Q4 2024MRKMerck & Co., Inc.$1.85$1.72-$0.13$1.48$15.51 billion$15.62 billion1/31/2025Q4 24ABBVAbbVie$2.98$2.16-$0.82-$0.02$14.81 billionN/A1/22/2025Q4 2024JNJJohnson & Johnson$1.99$2.04+$0.05$1.41$22.44 billion$22.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.20%+6.04%273.33%53 YearsJNJJohnson & Johnson$4.963.03%+5.43%74.59%63 YearsMRKMerck & Co., Inc.$3.243.63%+5.73%48.14%14 YearsLatest MRK, JNJ, and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025ABBVAbbViequarterly$1.643.4%4/15/20254/15/20255/15/20251/28/2025MRKMerck & Co., Inc.quarterly$0.813.32%3/17/20253/17/20254/7/20251/2/2025JNJJohnson & Johnsonquarterly$1.243.43%2/18/20252/18/20253/4/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie17.940.660.55JNJJohnson & Johnson0.431.110.86MRKMerck & Co., Inc.0.791.361.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%JNJJohnson & Johnson69.55%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%JNJJohnson & Johnson0.16%MRKMerck & Co., Inc.0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie50,0001.77 billion1.76 billionOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableMRKMerck & Co., Inc.69,0002.53 billion2.53 billionOptionableMRK, JNJ, and ABBV HeadlinesRecent News About These CompaniesWhy the Market Dipped But Merck (MRK) Gained TodayMarch 28 at 6:50 PM | zacks.comMRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud LawsuitMarch 28 at 5:39 PM | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck & Co., Inc. Lawsuit - MRKMarch 28 at 3:25 PM | accessnewswire.comMerck & Co., Inc. (NYSE:MRK) Stock Price Up 2.2% - Here's WhyMarch 28 at 3:23 PM | marketbeat.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRKMarch 28 at 3:00 PM | accessnewswire.comFDA Accepts Merck's Filing for Subcutaneous Version of KeytrudaMarch 28 at 12:20 PM | zacks.comLevi & Korsinsky Reminds Merck & Co., Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRKMarch 28 at 10:25 AM | accessnewswire.comWhich Dow Jones Stock Is Cheaper, Amgen or Merck?March 28 at 8:30 AM | fool.comShareholders of Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRKMarch 28 at 7:30 AM | accessnewswire.comDnB Asset Management AS Raises Position in Merck & Co., Inc. (NYSE:MRK)March 28 at 7:19 AM | marketbeat.comAlerus Financial NA Sells 41,592 Shares of Merck & Co., Inc. (NYSE:MRK)March 28 at 7:12 AM | marketbeat.comMRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!March 28 at 7:00 AM | accessnewswire.comdenkapparat Operations GmbH Acquires Shares of 14,882 Merck & Co., Inc. (NYSE:MRK)March 28 at 6:57 AM | marketbeat.com5,293 Shares in Merck & Co., Inc. (NYSE:MRK) Purchased by Tepp RIA LLCMarch 28 at 6:41 AM | marketbeat.comNomura Asset Management Co. Ltd. Cuts Stock Position in Merck & Co., Inc. (NYSE:MRK)March 28 at 6:41 AM | marketbeat.comBroadway Wealth Solutions Inc. Acquires New Holdings in Merck & Co., Inc. (NYSE:MRK)March 28 at 6:36 AM | marketbeat.com133,882 Shares in Merck & Co., Inc. (NYSE:MRK) Purchased by New Age Alpha Advisors LLCMarch 28 at 6:24 AM | marketbeat.comProvidence Capital Advisors LLC Has $7.49 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)March 28 at 6:08 AM | marketbeat.comLost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyMarch 28 at 5:45 AM | prnewswire.com7,892 Shares in Merck & Co., Inc. (NYSE:MRK) Bought by AssuredPartners Investment Advisors LLCMarch 28 at 5:39 AM | marketbeat.comArtisan Partners Limited Partnership Acquires 344,457 Shares of Merck & Co., Inc. (NYSE:MRK)March 28 at 5:21 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyVolatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsBy Gabriel Osorio-Mazilli | February 27, 2025View Volatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsAbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketBy Chris Markoch | March 23, 2025View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketResilient Investing: 3 Stocks Built to Weather Market VolatilityBy Jeffrey Neal Johnson | March 17, 2025View Resilient Investing: 3 Stocks Built to Weather Market VolatilityMRK, JNJ, and ABBV Company DescriptionsAbbVie NYSE:ABBV$205.12 +2.40 (+1.18%) Closing price 03:59 PM EasternExtended Trading$203.69 -1.43 (-0.70%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Johnson & Johnson NYSE:JNJ$163.63 +0.50 (+0.31%) Closing price 03:59 PM EasternExtended Trading$163.36 -0.27 (-0.17%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Merck & Co., Inc. NYSE:MRK$89.18 +1.58 (+1.80%) Closing price 03:59 PM EasternExtended Trading$89.15 -0.03 (-0.03%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Microsoft’s Big Malaysia Bet Could Pay Off for Investors Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
